|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
|
|
XFOR's Capital Expenditures Growth by Quarter and Year
X4 Pharmaceuticals Inc's Capital Expenditures results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Capital Expenditures Growth Y/Y▼
|
Capital Expenditures Growth Y/Y▼
|
XFOR Capital Expenditures (in millions $) |
FY 2025 |
FY 2024 |
FY 2023 |
FY 2022 |
4th Quarter |
December |
-
|
7.04
|
0.01
|
0.01
|
3rd Quarter |
September |
-
|
0.09
|
0.01
|
0.04
|
2nd Quarter |
June |
-
|
0.13
|
0.00
|
0.02
|
1st Quarter |
March |
0.00
|
0.06
|
0.03
|
0.01
|
FY |
|
0.00
|
7.32
|
0.05
|
0.08
|
XFOR Capital Expenditures first quarter 2025 Y/Y Growth Comment |
X4 Pharmaceuticals Inc in the first quarter 2025 recorded Capital Expenditures of $ 0.00 millions.
Looking into first quarter 2025 results within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Capital Expenditures growth. While X4 Pharmaceuticals Inc' s Capital Expenditures meltdown of -100% ranks overall at the positon no. 387 in the first quarter 2025.
|
XFOR Capital Expenditures ( Y/Y Growth %) |
2025
|
2024 |
2023 |
2022 |
4th Quarter |
December |
- |
70300 % |
0 % |
-50 % |
3rd Quarter |
September |
- |
800 % |
-75 % |
-55.56 % |
2nd Quarter |
June |
- |
- |
- |
-96 % |
1st Quarter |
March |
- |
100 % |
200 % |
-96.67 % |
FY |
|
- |
14540 % |
-37.5 % |
-91.21 % |
XFOR Capital Expenditures (Quarter on Quarter Growth %) |
2025
|
2024 |
2023 |
2022 |
4th Quarter |
December |
- |
7722.22 % |
0 % |
-75 % |
3rd Quarter |
September |
- |
-30.77 % |
- |
100 % |
2nd Quarter |
June |
- |
116.67 % |
- |
100 % |
1st Quarter |
March |
- |
500 % |
200 % |
-50 % |
FY (Year on Year) |
|
- |
14540 % |
-37.5 % |
-91.21 % |
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
89.56 % |
-33.01 % |
-93.26 % |
(Jun 30 2021) |
|
(Jun 30 2022) |
|
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
89.56 % |
-33.01 % |
-93.26 % |
(Jun 30 2021) |
|
(Jun 30 2022) |
|
Capital Expenditures by Quarter for the Fiscal Years 2022, 2023, 2024, 2025 |
X4 Pharmaceuticals Inc's Q/Q Capital Expenditures Growth
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
XFOR's I. Quarter Q/Q Capital Expenditures Comment |
Recent accomplishment of 0.00 millions by X4 Pharmaceuticals Inc come out even worse considering the 7.04 millions a quarter before.
Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While X4 Pharmaceuticals Inc's Capital Expenditures growth quarter on quarter, overall rank is . |
|
|
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
XFOR's I. Quarter Q/Q Capital Expenditures Comment |
Recent accomplishment of 0.00 millions by X4 Pharmaceuticals Inc come out even worse considering the 7.04 millions a quarter before.
Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While X4 Pharmaceuticals Inc's Capital Expenditures growth quarter on quarter, overall rank is . |
|
X4 Pharmaceuticals Inc's 12 Months Capital Expenditures Growth Year on Year
Capital Expenditures TTM Growth |
12 Months Ending (Mar 31 2025) |
12 Months Ending (Dec 31 2024) |
12 Months Ending (Sep 30 2024) |
12 Months Ending (Jun 30 2024) |
12 Months Ending (Mar 31 2024) |
Cumulative Capital Expenditures 12 Months Ending |
$ 0.00 |
$ 7.33 |
$ 0.29 |
$ 0.21 |
$ 0.00 |
Y / Y Capital Expenditures Growth (TTM) |
- |
- |
- |
- |
- |
Year on Year Capital Expenditures Growth Overall
Ranking |
# |
# |
# |
# |
# |
Seqeuential Capital Expenditures Change (TTM) |
- |
2400.34 % |
40.19 % |
- |
- |
Seq. Capital Expenditures Growth (TTM) Overall
Ranking |
# 387 |
# 465 |
# 456 |
# 0 |
# 347 |
Cumulative Capital Expenditures growth Comment |
In the Mar 31 2025 period, X4 Pharmaceuticals Inc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.
X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. . |
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 7 |
Sector |
# 58 |
S&P 500 |
# 387 |
|
Cumulative Capital Expenditures growth
Comment |
In the Mar 31 2025 period, X4 Pharmaceuticals Inc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.
X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. . |
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 7 |
Sector |
# 58 |
S&P 500 |
# 387 |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com